Adaptive Biotechnologies COO Executes Stock Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ADPT?
Source: NASDAQ.COM
- Executive Stock Sale: COO Julie Rubinstein sold 19,037 shares on April 27, 2026, at an average price of approximately $14.23 per share, totaling around $271,000, which reduced her direct holdings by 4.8%, indicating continued executive engagement with the company's stock.
- Options Exercise Details: The transaction involved the exercise of 14,707 options executed directly without indirect participation, demonstrating Rubinstein's adherence to a Rule 10b5-1 trading plan, thereby mitigating insider trading concerns.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, although it faced an operating loss of $57.1 million, significantly down from a $162.5 million loss in 2024, indicating improved cost management.
- Market Outlook Analysis: Despite the stock price retreating from its 52-week high of $20.76, investors should monitor the company's potential for future sales growth, especially as operating costs are expected to rise modestly, suggesting a possible buying opportunity at current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.810
Low
20.00
Averages
20.86
High
22.00
Current: 13.810
Low
20.00
Averages
20.86
High
22.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adaptive Biotechnologies Reports Strong Q1 2026 Earnings with Revenue Growth
- MRD Revenue Growth: Adaptive Biotechnologies reported a 53% year-over-year increase in MRD revenue for Q1 2026, reaching $67.1 million, indicating strong performance in precision medicine and likely enhancing future market share.
- Margin Improvement: The company's sequencing gross margin rose to 70% this quarter, an 8 percentage point increase from the previous year, reflecting improved cost control and operational efficiency, which is expected to bolster investor confidence.
- Strong Cash Position: At the end of the quarter, the company had approximately $222 million in cash reserves, ensuring financial flexibility for future R&D and market expansion, supporting its long-term growth strategy.
- Upward Revenue Guidance: The company raised its full-year MRD revenue guidance to a range of $260 million to $270 million, reflecting management's optimistic outlook on market demand while emphasizing ongoing cost control efforts.
See More
Adaptive Biotechnologies Executive Stock Transaction Overview
- Transaction Overview: On April 27, 2026, Adaptive Biotechnologies' COO Julie Rubinstein exercised 14,707 options and sold 19,037 shares of common stock for approximately $271,000, while retaining 377,802 shares valued at about $5.37 million, indicating continued confidence in the company.
- Ownership Change: The 19,037 shares sold represented 4.8% of Rubinstein's direct common stock holdings, reflecting a modest reduction in her equity exposure, yet she maintains a significant economic interest in the firm.
- Planned Trading Context: Rubinstein's transaction was executed under a Rule 10b5-1 trading plan established in November 2025, which is typically used by executives to mitigate insider trading allegations, suggesting her actions were strategic rather than impulsive.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, despite an operating loss of $57.1 million, which is a significant improvement from the previous year's loss of $162.5 million, indicating potential for cost control and sales growth moving forward.
See More
Adaptive Biotechnologies COO Executes Stock Sale
- Executive Stock Sale: COO Julie Rubinstein sold 19,037 shares on April 27, 2026, at an average price of approximately $14.23 per share, totaling around $271,000, which reduced her direct holdings by 4.8%, indicating continued executive engagement with the company's stock.
- Options Exercise Details: The transaction involved the exercise of 14,707 options executed directly without indirect participation, demonstrating Rubinstein's adherence to a Rule 10b5-1 trading plan, thereby mitigating insider trading concerns.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, although it faced an operating loss of $57.1 million, significantly down from a $162.5 million loss in 2024, indicating improved cost management.
- Market Outlook Analysis: Despite the stock price retreating from its 52-week high of $20.76, investors should monitor the company's potential for future sales growth, especially as operating costs are expected to rise modestly, suggesting a possible buying opportunity at current levels.
See More
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
- Transaction Overview: Julie Rubinstein sold 57,180 shares of common stock between April 9 and April 13, 2026, for approximately $758,000, while still holding 421,174 shares directly valued at about $5.95 million, indicating a strategic reduction in her holdings.
- Trading Pattern Analysis: The transaction involved exercising 44,166 vested options and selling 57,180 shares, reflecting a 19.4% decline in her direct holdings since mid-March 2026, suggesting a gradual divestment strategy.
- Ownership Impact Assessment: The sale represented 11.95% of Rubinstein's direct common stock position; however, she retains 192,936 unexercised options, indicating a substantial long-term economic interest in the company.
- Investor Focus: Rubinstein's stock sales are part of a pre-arranged 10b5-1 plan established in November 2026, indicating that these transactions do not signal her current sentiment towards the stock, prompting investors to monitor the growth of clonoSEQ volumes and biopharma collaboration revenues instead.
See More
Adaptive Biotechnologies Executive Stock Sale
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of Common Stock in open-market transactions from April 14 to 16, 2026, totaling approximately $826,000, which represents a 12.29% reduction in her direct holdings to 408,160 shares.
- Sale Context: The shares sold were acquired through the exercise of options at a weighted average price of around $14.45 per share, despite a market close price of $14.08, indicating that the sale may be more about supplementing income rather than a lack of confidence in the company's future.
- Holding Structure Change: During the four-day period from April 9 to 13, Rubinstein also reduced her direct holdings by 27,736 shares, yet she still retains 408,160 shares and 148,770 stock options, aligning her interests with those of shareholders.
- Growth Potential: Revenue from Adaptive Biotechnologies' minimal residual disease monitoring services rose 46% last year, and the business is poised for further growth in 2026, particularly after receiving expanded Medicare coverage for mantle cell lymphoma patients, highlighting the company's market potential in cancer monitoring.
See More
Adaptive Biotechnologies Executive Sells Shares
- Transaction Overview: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of common stock in open-market transactions between April 14 and 16, 2026, totaling approximately $826,000, indicating a liquidity need from the executive.
- Impact on Holdings: Following the sale, Rubinstein's direct ownership decreased by 12.29%, leaving her with 408,160 shares, suggesting that future transactions may be constrained by the reduced share count, potentially affecting her influence over the company.
- Transaction Context: The sale involved the exercise of 44,166 options for common stock, with all resulting shares sold immediately, demonstrating a liquidity event rather than a long-term holding disposition, reflecting the executive's financial obligations.
- Company Performance Outlook: Despite the insider selling, Adaptive Biotechnologies' revenue from minimal residual disease (MRD) cancer monitoring services rose 46% last year and is poised for further growth in 2026, highlighting the company's market potential and future growth opportunities.
See More
Adaptive Biotechnologies Reports Strong Q1 2026 Earnings with Revenue Growth
- MRD Revenue Growth: Adaptive Biotechnologies reported a 53% year-over-year increase in MRD revenue for Q1 2026, reaching $67.1 million, indicating strong performance in precision medicine and likely enhancing future market share.
- Margin Improvement: The company's sequencing gross margin rose to 70% this quarter, an 8 percentage point increase from the previous year, reflecting improved cost control and operational efficiency, which is expected to bolster investor confidence.
- Strong Cash Position: At the end of the quarter, the company had approximately $222 million in cash reserves, ensuring financial flexibility for future R&D and market expansion, supporting its long-term growth strategy.
- Upward Revenue Guidance: The company raised its full-year MRD revenue guidance to a range of $260 million to $270 million, reflecting management's optimistic outlook on market demand while emphasizing ongoing cost control efforts.
See More
Adaptive Biotechnologies Executive Stock Transaction Overview
- Transaction Overview: On April 27, 2026, Adaptive Biotechnologies' COO Julie Rubinstein exercised 14,707 options and sold 19,037 shares of common stock for approximately $271,000, while retaining 377,802 shares valued at about $5.37 million, indicating continued confidence in the company.
- Ownership Change: The 19,037 shares sold represented 4.8% of Rubinstein's direct common stock holdings, reflecting a modest reduction in her equity exposure, yet she maintains a significant economic interest in the firm.
- Planned Trading Context: Rubinstein's transaction was executed under a Rule 10b5-1 trading plan established in November 2025, which is typically used by executives to mitigate insider trading allegations, suggesting her actions were strategic rather than impulsive.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, despite an operating loss of $57.1 million, which is a significant improvement from the previous year's loss of $162.5 million, indicating potential for cost control and sales growth moving forward.
See More
Adaptive Biotechnologies COO Executes Stock Sale
- Executive Stock Sale: COO Julie Rubinstein sold 19,037 shares on April 27, 2026, at an average price of approximately $14.23 per share, totaling around $271,000, which reduced her direct holdings by 4.8%, indicating continued executive engagement with the company's stock.
- Options Exercise Details: The transaction involved the exercise of 14,707 options executed directly without indirect participation, demonstrating Rubinstein's adherence to a Rule 10b5-1 trading plan, thereby mitigating insider trading concerns.
- Company Financial Performance: Adaptive Biotechnologies reported $277 million in sales for 2025, a 55% increase year-over-year, although it faced an operating loss of $57.1 million, significantly down from a $162.5 million loss in 2024, indicating improved cost management.
- Market Outlook Analysis: Despite the stock price retreating from its 52-week high of $20.76, investors should monitor the company's potential for future sales growth, especially as operating costs are expected to rise modestly, suggesting a possible buying opportunity at current levels.
See More
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
- Transaction Overview: Julie Rubinstein sold 57,180 shares of common stock between April 9 and April 13, 2026, for approximately $758,000, while still holding 421,174 shares directly valued at about $5.95 million, indicating a strategic reduction in her holdings.
- Trading Pattern Analysis: The transaction involved exercising 44,166 vested options and selling 57,180 shares, reflecting a 19.4% decline in her direct holdings since mid-March 2026, suggesting a gradual divestment strategy.
- Ownership Impact Assessment: The sale represented 11.95% of Rubinstein's direct common stock position; however, she retains 192,936 unexercised options, indicating a substantial long-term economic interest in the company.
- Investor Focus: Rubinstein's stock sales are part of a pre-arranged 10b5-1 plan established in November 2026, indicating that these transactions do not signal her current sentiment towards the stock, prompting investors to monitor the growth of clonoSEQ volumes and biopharma collaboration revenues instead.
See More
Adaptive Biotechnologies Executive Stock Sale
- Executive Stock Sale: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of Common Stock in open-market transactions from April 14 to 16, 2026, totaling approximately $826,000, which represents a 12.29% reduction in her direct holdings to 408,160 shares.
- Sale Context: The shares sold were acquired through the exercise of options at a weighted average price of around $14.45 per share, despite a market close price of $14.08, indicating that the sale may be more about supplementing income rather than a lack of confidence in the company's future.
- Holding Structure Change: During the four-day period from April 9 to 13, Rubinstein also reduced her direct holdings by 27,736 shares, yet she still retains 408,160 shares and 148,770 stock options, aligning her interests with those of shareholders.
- Growth Potential: Revenue from Adaptive Biotechnologies' minimal residual disease monitoring services rose 46% last year, and the business is poised for further growth in 2026, particularly after receiving expanded Medicare coverage for mantle cell lymphoma patients, highlighting the company's market potential in cancer monitoring.
See More
Adaptive Biotechnologies Executive Sells Shares
- Transaction Overview: Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of common stock in open-market transactions between April 14 and 16, 2026, totaling approximately $826,000, indicating a liquidity need from the executive.
- Impact on Holdings: Following the sale, Rubinstein's direct ownership decreased by 12.29%, leaving her with 408,160 shares, suggesting that future transactions may be constrained by the reduced share count, potentially affecting her influence over the company.
- Transaction Context: The sale involved the exercise of 44,166 options for common stock, with all resulting shares sold immediately, demonstrating a liquidity event rather than a long-term holding disposition, reflecting the executive's financial obligations.
- Company Performance Outlook: Despite the insider selling, Adaptive Biotechnologies' revenue from minimal residual disease (MRD) cancer monitoring services rose 46% last year and is poised for further growth in 2026, highlighting the company's market potential and future growth opportunities.
See More
